Conmed Corporation reported net sales of $343.5 million [1] for the second quarter ending June 2026.

The results provide a critical snapshot of the company's financial health and market position as it navigates fluctuating currency values and global demand for medical devices.

Net sales for the period rose 0.3% [1] on a reported basis. However, the company saw a 0.5% [1] decrease in net sales when measured in constant currency. This discrepancy highlights the impact of exchange rate volatility on the company's bottom line during the quarter.

Despite the flat sales growth, the company exceeded analyst expectations for the period. Yahoo Finance said Conmed delivered an earnings surprise of 25.46% [4] and a revenue surprise of 1.85% [5] for the quarter ended June 2026.

The company shared these details during its second-quarter 2026 results and earnings call presentation. The data reflects the company's performance across its various medical technology segments as it reports to the New York Stock Exchange.

Financial analysts often monitor these "surprises" to determine if a company is managing its costs more effectively than predicted, even when top-line revenue remains stagnant. The gap between reported and constant currency sales is a common metric for multinational corporations operating in diverse economic zones.

“Conmed (CNMD) delivered earnings and revenue surprises of +25.46% and +1.85%, respectively”

The divergence between reported growth and constant currency decline suggests that Conmed's organic growth is slightly negative, but favorable currency swings are masking that dip in the primary reporting. The significant earnings surprise indicates that the company likely improved its operational efficiency or reduced expenses, allowing it to beat profit expectations despite a lack of strong revenue momentum.